Disclosure regarding Rameda acquiring a selection of pharmaceutical products belong to diabetes and cholesterol treatment drugs Regulatory DisclosuresBy adminJune 1, 2023
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. finalizes acquisition of a portfolio of 11 fast-growing cardiometabolic products Corporate NewsBy adminJune 1, 2023
Details Standalone financial statements for the period ended 31 March 2023Standalone Financial StatementsBy adminMay 15, 2023
Details Consolidated financial statements for the period ended 31 March 2023Consolidated Financial Statements resultsBy adminMay 15, 2023
